ORMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oramed Pharmaceuticals Inc (ORMP) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive catalysts, has weak financial performance, and no significant trading signals or trends to support a buy decision. Holding off on this investment is recommended until stronger signals or improvements in fundamentals emerge.
The technical indicators suggest a neutral trend. The MACD is below 0 and negatively contracting, RSI is neutral at 50.674, and moving averages are converging. Key support and resistance levels are close to the current price, indicating limited momentum in either direction.
NULL identified. There is no recent news, no significant insider or hedge fund activity, and no congress trading data.
The company's financial performance is a major concern. Net income dropped significantly by -346.67% YoY in Q3 2025, and EPS fell by -335.42% YoY. Additionally, the pre-market price is down -1.78%, and the stock has a low probability of significant short-term gains.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$48.4 million, down -346.67% YoY. EPS also fell significantly by -335.42% YoY to 1.13. Gross margin increased slightly to 0.65 but remains negligible in the context of overall poor financial performance.
No recent analyst ratings or price target changes available for ORMP.
